Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CRSP
CRISPR Therapeutics AG
stock NASDAQ

At Close
Jun 20, 2025 3:59:58 PM EDT
44.23USD-0.450%(-0.20)3,055,908
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 20, 2025 9:28:30 AM EDT
45.00USD+1.283%(+0.57)42,093
After-hours
Jun 20, 2025 4:38:30 PM EDT
44.31USD+0.181%(+0.08)1,944
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
07:08AM EST  Crisper Therapeutics Shares Spike to Premarket High +4.36   Benzinga
Jan 25, 2022
02:08PM EST  Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years   Benzinga
Dec 21, 2021
02:53PM EST  'CRISPR Therapeutics could set a milestone by filing for approval before the end of 2022 with its sickle cell/beta thal treatment...' -Tweet From Business Insider Pharma Reporter   Benzinga
Dec 14, 2021
02:51PM EST  CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine'   Benzinga
Dec 7, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021   Benzinga
04:58AM EST  Cowen & Co. Initiates Coverage On CRISPR Therapeutics with Market Perform Rating   Benzinga
Nov 23, 2021
08:38AM EST  CRISPR Therapeutics To Participate In 2 Upcoming Events: Evercore ISI HealthCONx Conference Dec. 1 At 12:35 p.m. EST, Piper Sandler Healthcare Conference Dec. 2 At 1 p.m. EST   Benzinga
08:30AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in December:   GlobeNewswire Inc
Nov 22, 2021
01:20PM EST  CRISPR Therapeutics Option Alert: Apr 14 $125 Calls Sweep (11) near the Ask: 99 @ $3.601 vs 1686 OI; Ref=$81.08   Benzinga
08:32AM EST  CRISPR Therapeutics Reports FDA Regenerative Medicine Advanced Therapy Designation Granted For Co.'s CTX110 For Treatment Of Relapses, Refractory CD19+ B-Cell Malignancies   Benzinga
08:30AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.   GlobeNewswire Inc
Nov 16, 2021
08:34AM EST  CRISPR Therapeutics And ViaCyte, Inc. To Start Clinical Trial Of The First Gene-Edited Cell Replacement Therapy For Treatment Of Type 1 Diabetes   Benzinga
08:30AM EST  CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of   GlobeNewswire Inc
Nov 4, 2021
07:37AM EDT  Barclays Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $148   Benzinga
Nov 3, 2021
04:35PM EDT  CRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY   Benzinga
04:01PM EDT  -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022-   GlobeNewswire Inc
Nov 2, 2021
10:57AM EDT  CRISPR Therapeutics to Participate in Upcoming Investor Conferences; Credit Suisse 30th Annual Healthcare Conference Nov. 8 And Barclays Gene Editing & Gene Therapy Summit Nov. 15   Benzinga
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in November:   GlobeNewswire Inc
Oct 19, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
06:16AM EDT  SVB Leerink Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $126   Benzinga
Oct 14, 2021
08:07AM EDT  The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts   Benzinga
07:33AM EDT  Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Thursday the appointment of Brendan Smith as Chief Financial Officer, effective today. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio.   RTTNews
07:20AM EDT  CRISPR Therapeutics Appoints Brendan Smith As CFO   RTTNews
07:19AM EDT  CRISPR Therapeutics Announces The Appointment Of Brendan Smith As Chief Financial Officer   Benzinga
07:00AM EDT  CRISPR Therapeutics Announces Transition of Chief Financial Officer   GlobeNewswire Inc
Oct 13, 2021
01:38PM EDT  Stifel Maintains Hold on CRISPR Therapeutics, Lowers Price Target to $101   Benzinga
01:38PM EDT  Why CRISPR Therapeutics Stock Is Tumbling Today   Benzinga
01:38PM EDT  The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal   Benzinga
10:51AM EDT  Shares of CRISPR Therapeutics AG (CRSP) are slipping nearly 6% on Wednesday morning after reporting initial data from its CAR-T therapy candidate.   RTTNews
06:43AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT).   RTTNews
Oct 12, 2021
04:07PM EDT  'I spoke to $CRSP CEO Sam Kulkarni and @UrnovFyodor about the $ALLO "chromosomal abnormality"safety issue. Kulkarni said he thinks CTX110 won't be affected.' -Tweet From STAT News' Adam Feuerstein   Benzinga
04:03PM EDT  CRISPR Therapeutics Reports Results From Phase 1 CARBON Trial Of CTX110 In Relapsed, Refractory CD19+ B-Cell Malignancies: '58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose'   Benzinga
04:01PM EDT  -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-   GlobeNewswire Inc
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 5, 2021
04:12PM EDT  CRISPR Therapeutics To Host Virtual Event Highlighting CTX110 Clinical Data Oct. 12   Benzinga
04:05PM EDT  -Management to host conference call and webcast on October 12th at 4:30 p.m. ET-   GlobeNewswire Inc
Oct 1, 2021
08:23AM EDT  CRISPR Therapeutics To Present Preclinical Data At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting On Nov. 10   Benzinga
08:00AM EDT  CRISPR Therapeutics to Present Preclinical Data at the Society for   GlobeNewswire Inc
Sep 28, 2021
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Chardans 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET.   GlobeNewswire Inc
Aug 16, 2021
08:42AM EDT  Canaccord Genuity Maintains Buy on CRISPR Therapeutics, Raises Price Target to $160   Benzinga
Aug 5, 2021
10:23AM EDT  CRISPR Therapeutics Option Alert: Sep 17 $155 Calls Sweep (41) above Ask!: 963 @ $3.7 vs 23 OI; Ref=$129.78   Benzinga
Jul 30, 2021
09:51AM EDT  Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $171   Benzinga
Jul 29, 2021
05:24PM EDT  CRISPR Therapeutics Q2 EPS $9.44 Up From $(1.30) YoY   Benzinga
Jul 21, 2021
11:49AM EDT  Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?   Benzinga
Jul 14, 2021
07:24AM EDT  Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More   Benzinga
Jul 12, 2021
03:12PM EDT  WHO Issues Framework For Governance For Gene Editing Technologies   Benzinga
Jun 30, 2021
04:51PM EDT  'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond   Benzinga
Jun 21, 2021
04:06PM EDT  QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments   Benzinga
Jun 17, 2021
09:49AM EDT  Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More   Benzinga
Jun 15, 2021
08:06AM EDT  CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases   Benzinga
07:15AM EDT  CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich's Ataxia   Benzinga
07:15AM EDT  - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases -   GlobeNewswire Inc
Jun 14, 2021
10:47AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021   Benzinga
09:32AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:53AM EDT  Citigroup Upgrades CRISPR Therapeutics to Neutral, Raises Price Target to $132   Benzinga
Jun 11, 2021
10:33AM EDT  Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials   Benzinga
03:12AM EDT  Vertex, CRISPR Announce New Data On 22 Patients Treated With Investigational CRISPR/Cas9-based Gene-editing Therapy   RTTNews
03:05AM EDT  Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001(tm) at European Hematology Association Annual Meeting   Business Wire
May 25, 2021
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June:   GlobeNewswire Inc
May 12, 2021
11:03AM EDT  Vertex, CRISPR Therapeutics To Present New Clinical Data On Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies At Annual European Hematology Association Virtual Congress   Benzinga
11:00AM EDT  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress.   GlobeNewswire Inc
May 7, 2021
11:40AM EDT  Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer   Benzinga
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
04:15PM EDT  CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer   Benzinga
04:01PM EDT  -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities-   GlobeNewswire Inc
Apr 29, 2021
08:30AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May:   GlobeNewswire Inc
Apr 28, 2021
04:01PM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.   GlobeNewswire Inc
Apr 27, 2021
04:19PM EDT  CRISPR Therapeutics Q1 EPS $(1.51) Down From $(1.15) YoY, Sales $539.00K Up From $157.00K YoY   Benzinga
04:01PM EDT  - Granted Priority Medicines designation by the European Medicines Agency for CTX001 for transfusion-dependent beta thalassemia (TDT)-   GlobeNewswire Inc
Apr 26, 2021
08:34AM EDT  Vertex, CRISPR Report Priority Medicines Designation Granted By European Medicines Agency For Its Transfusion-Dependent Beta Thalassemia Candidate   Benzinga
08:30AM EDT  Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME)   GlobeNewswire Inc
Apr 21, 2021
01:59PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021   Benzinga
10:17AM EDT  Barclays Maintains Overweight on CRISPR Therapeutics, Raises Price Target to $160   Benzinga
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021   Benzinga
08:03AM EDT  Jefferies Upgrades CRISPR Therapeutics to Buy, Announces $172 Price Target   Benzinga
Apr 20, 2021
02:40PM EDT  Mid-Afternoon Market Update: Dow Tumbles 370 Points; Kansas City Southern Shares Spike Higher   Benzinga
10:14AM EDT  Beam Therapeutics Publishes Data Highlighting Ability To Rationally Design Base Editors For Precise Editing   Benzinga
07:20AM EDT  Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia   Benzinga
07:15AM EDT  - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-   GlobeNewswire Inc
Apr 10, 2021
08:31AM EDT  CRISPR Therapeutics Presents Preclinical Data at AACR 2021   GlobeNewswire Inc
Apr 6, 2021
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 9:30 a.m. ET.   GlobeNewswire Inc
Mar 29, 2021
11:37AM EDT  PerkinElmer's Horizon Discovery Says Extends Gene Modulation Portfolio With 'Industry First' Synthetic Single Guide RNA And Patent Pending dCas9 Repressor For CRISPR Interface   Benzinga
Mar 10, 2021
05:03PM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.   GlobeNewswire Inc
Mar 4, 2021
10:10AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2021   Benzinga
08:07AM EST  JMP Securities Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $160   Benzinga
Mar 3, 2021
08:00AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:   GlobeNewswire Inc
Mar 1, 2021
11:33AM EST  Barclays Maintains Overweight on CRISPR Therapeutics, Raises Price Target to $140   Benzinga
Feb 17, 2021
12:27PM EST  Oppenheimer Maintains Outperform on CRISPR Therapeutics, Raises Price Target to $187   Benzinga
Feb 16, 2021
04:02PM EST  CRISPR Therapeutics Q4 Net Loss $107M vs Net Income $30.5M In Same Qtr. Last Year, Sales $200.00K Down From $77.02M YoY   Benzinga
04:01PM EST  -More than 20 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -   GlobeNewswire Inc
Feb 5, 2021
08:00AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.   GlobeNewswire Inc
Feb 1, 2021
08:03AM EST  CRISPR Therapeutics Announces Appointment Of Philippe Drouet As CCO   Benzinga
08:00AM EST  CRISPR Therapeutics Announces the Appointment of Philippe Drouet   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
12:14PM EST  On CNBC: Trader Kari Firestone Says Valuation In CRISPR, CrowdStrike Got Ahead Of Themselves   Benzinga
11:31AM EST  Cramer Weighs In On Salesforce, General Motors And More   Benzinga
Dec 22, 2020
10:02AM EST  Return On Capital Employed Overview: CRISPR Therapeutics   Benzinga
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 14, 2020
08:04AM EST  CRISPR Therapeutics Reports Receipt Of Grant From Bill & Melinda Gates Foundation To Research In Vivo Gene Therapies For Treatment Of HIV   Benzinga
08:00AM EST  -Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-   GlobeNewswire Inc
Dec 11, 2020
08:19AM EST  CRISPR Therapeutics AG SAYs Entered Into Open Market Sale Agreement With Jefferies; Says May Offer, Sell Up To $350M In Common Stock   Benzinga
Dec 10, 2020
08:31AM EST  Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $166   Benzinga
06:20AM EST  Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $170   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
10:10AM EST  Benzinga's Top Upgrades, Downgrades For December 7, 2020   Benzinga
08:37AM EST  Roth Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $170   Benzinga
06:59AM EST  Wells Fargo Downgrades CRISPR Therapeutics to Equal-Weight, Announces $145 Price Target   Benzinga
Dec 6, 2020
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 5, 2020
01:18PM EST  CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at ASH, Together With Publication in NEJM   Benzinga
12:30PM EST  - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -   GlobeNewswire Inc
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
09:15AM EST  CRISPER Therapeutics, Vertex To Host Investor Webcast To Review Data Presented At 62nd American Society Of Hematology Metting And Exposition For Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 In Sickle Cell Disease And Beta Thalassemia   Benzinga
09:00AM EST  CRISPR Therapeutics and Vertex to Host Investor Webcast to Review   GlobeNewswire Inc
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 24, 2020
08:00AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.   GlobeNewswire Inc
Nov 16, 2020
08:00AM EST  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, November 19, 2020, at 12:00 p.m. ET.   GlobeNewswire Inc
Nov 4, 2020
09:17AM EST  CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies Accepted For Plenary Presentation At 62nd American Society Of Hematology Meeting And Exposition   Benzinga
09:15AM EST  CRISPR/Cas9 Gene-Editing Therapy CTX001 for   GlobeNewswire Inc
Oct 29, 2020
09:25AM EDT  Piper Sandler Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $107   Benzinga
Oct 28, 2020
08:05AM EDT  CRISPR Therapeutics Q3 EPS $(1.32) Down From $2.40 YoY, Sales $148.00K Down From $211.93M YoY   Benzinga
08:00AM EDT  -Reported positive top-line results from the Companys ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, targeting CD19+ B-cell malignancies-   GlobeNewswire Inc
Oct 23, 2020
10:48AM EDT  Benzinga's Top Upgrades, Downgrades For October 23, 2020   Benzinga
06:07AM EDT  RBC Capital Initiates Coverage On CRISPR Therapeutics with Sector Perform Rating, Announces Price Target of $110   Benzinga
Oct 22, 2020
10:53AM EDT  CRISPR Therapeutics shares are trading higher after Chardan Capital maintained its Buy rating on the stock and raised its price target from $100 to $110 per share.   Benzinga
08:41AM EDT  Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $110   Benzinga
Oct 21, 2020
02:30PM EDT  CRISPR Therapeutics Shares Quiet; Roth Capital Raises Price Target To $115; Says 'We've now seen early, but positive, results from CRISPR and Allogene'   Benzinga
09:58AM EDT  Shares of CRISPR Therapeutics AG (CRSP) slipped over 10% on Wednesday morning. The drug maker reported positive results from its phase 1 study of lymphoma therapy, however, one patient died during the trial.   RTTNews
09:07AM EDT  CRISPR Reports Positive Top-Line Results From Phase 1   RTTNews
08:47AM EDT  CRISPR Reports Positive Top-line Results From Ongoing Phase 1 CARBON Trial On CTX110   RTTNews
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
07:12AM EDT  '$CRSP off-the-shelf CAR-T treatment shows encouraging results, but one death is tied to therapy' -STAT's Adam Feuerstein   Benzinga
07:11AM EDT  CRISPR Therapeutics Reports Top-Line Results From Phase 1 CARBON Trial of CTX110; Showed 50% Complete Response Rate, Early Evidence Of Dose-Dependent Responses   Benzinga
07:00AM EDT  -50% (2/4) complete response (CR)rate at three months in the Dose Level 3 (DL3)cohort; both respondersremain in CR-   GlobeNewswire Inc
Oct 12, 2020
03:54PM EDT  'Fast Money Halftime Report' Picks For October 12   Benzinga
Oct 9, 2020
12:26PM EDT  Cramer Weighs In On Virgin Galactic, Boeing And More   Benzinga
Oct 8, 2020
08:16AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Oct. 8, 2020: TSLA, JNJ, ROKU, IH, EDIT   Benzinga
Oct 7, 2020
09:26AM EDT  CRISPR Therapeutics Congratulates Co-Founder Emmanuelle   GlobeNewswire Inc
Oct 5, 2020
10:19AM EDT  Benzinga's Top Upgrades, Downgrades For October 5, 2020   Benzinga
07:23AM EDT  B of A Securities Initiates Coverage On CRISPR Therapeutics with Buy Rating, Announces Price Target of $110   Benzinga
Sep 29, 2020
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in October:   GlobeNewswire Inc
Sep 22, 2020
09:16AM EDT  CRISPR Therapeutics, Vertex Announce EMA Granted Priority Medicines Designation To CTX001   RTTNews
09:05AM EDT  CRISPR Therapeutics And Vertex Pharmaceuticals Announce Priority Medicines Designation Granted By European Medicines Agency To CTX001 For Treatment Of Sickle Cell Disease   Benzinga
09:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease (SCD).   GlobeNewswire Inc
Sep 3, 2020
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET.   GlobeNewswire Inc
Aug 12, 2020
10:53AM EDT  CRISPR Therapeutics Option Alert: Aug 21 $100 Calls at the Ask: 300 @ $1.0 vs 2400 OI; Ref=$90.62   Benzinga
Jul 30, 2020
08:00AM EDT  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August:   GlobeNewswire Inc
Jul 28, 2020
11:28AM EDT  Barclays Maintains Overweight on CRISPR Therapeutics, Raises Price Target to $102   Benzinga
08:04AM EDT  Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $100   Benzinga
06:32AM EDT  Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $105   Benzinga
Jul 27, 2020
04:31PM EDT  CRISPR Therapeutics Q2 Net Loss $79.7M vs Net Loss $53.7M In Same Qtr. Last Year, Sales $100K vs $300K Year Over Year   Benzinga
04:30PM EDT  -Dosing re-initiated in clinical trials of CTX001 for patients with severe hemoglobinopathies-   GlobeNewswire Inc
Jul 25, 2020
01:30PM EDT  Barron's Picks And Pans: Crispr, McDonald's, Nikola And More   Benzinga
Jul 14, 2020
09:57AM EDT  Benzinga's Top Upgrades, Downgrades For July 14, 2020   Benzinga
06:02AM EDT  SunTrust Robinson Humphrey Initiates Coverage On CRISPR Therapeutics with Buy Rating, Announces Price Target of $140   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC